The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AMPLIFY ENERGY CORP NEW | COM | 03212B103 | 6,547 | 953 | SH | SOLE | 953 | 0 | 0 | |||
| CBL & ASSOC PPTYS INC | COMMON STOCK | 012430878 | 2,104,557 | 82,081 | SH | SOLE | 82,081 | 0 | 0 | |||
| FIRST REP BK SAN FRANCISCO C | COM | 33616C100 | 727,480 | 52,000 | SH | SOLE | 52,000 | 0 | 0 | |||
| INVESCO QQQ TR | UNIT SER 1 | 46090E103 | 1,540,464 | 4,800 | SH | SOLE | 4,800 | 0 | 0 | |||
| LANTHEUS HLDGS INC | COM | 516544103 | 8,256,000 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | |||
| NOVARTIS AG | SPONSORED ADR | 66987V109 | 2,024,000 | 22,000 | SH | SOLE | 22,000 | 0 | 0 | |||
| NOVO-NORDISK A S | ADR | 670100205 | 1,113,980 | 7,000 | SH | SOLE | 7,000 | 0 | 0 | |||
| SPDR S&P 500 ETF TR | TR UNIT | 78462F103 | 1,023,475 | 2,500 | SH | SOLE | 2,500 | 0 | 0 | |||
| UNITED THERAPEUTICS CORP DEL | COM | 91307C102 | 2,015,640 | 9,000 | SH | SOLE | 9,000 | 0 | 0 | |||
| GLOBAL CORD BLOOD CORPORATIO | SHS | G39342103 | 0 | 279,495 | SH | SOLE | 279,495 | 0 | 0 | |||